Most Read Articles
Rachel Soon, 08 Apr 2020

Guidelines for local pharmacists on what actions to take during the COVID-19 pandemic have been issued by the Malaysian Pharmaceutical Society (MPS).

Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Roshini Claire Anthony, 6 days ago

The use of a vaginal cleansing intervention prior to Caesarean delivery reduced the incidence of surgical site infections (SSIs), according to a study presented at ACOG 2020. However, the addition of intravenous (IV) azithromycin prophylaxis had no added impact on SSI rates. 

Long-term isradipine use does not prevent Parkinson’s disease progression

06 Apr 2020

Treatment with immediate-release isradipine, a dihydropyridine calcium-channel blocker, for 36 months has failed to slow the progression of early-stage Parkinson’s disease (PD), according to a study.

A total of 336 patients with early-stage PD not on any dopaminergic medications were randomly assigned (mean age, 62 years; 68 percent men) across 57 Parkinson Study Group sites in North America to receive 5 mg of immediate-release isradipine twice daily or placebo for 36 months.

Change in the Unified Parkinson's Disease Rating Scale (UPDRS) parts I to III score, measured in the antiparkinson medication “ON” state between baseline and 36 months, was the primary outcome. Secondary outcomes were as follows: time to initiation and use of antiparkinson medications, time to onset of motor complications, change in nonmotor disability, and quality-of-life measures.

Of the patients, 95 percent completed the study. The mean duration was 0.9 year, and the mean UPDRS part I to III score was 23.1.

Over the treatment period, adjusted least-squares mean changes in total UPDRS score in the antiparkinson medication ON state was 2.99 points (95 percent confidence interval [CI], 0.95–5.03) for isradipine and 3.26 points (95 percent CI, 1.25–5.26) for placebo. Treatment effect was –0.27 point (95 percent CI, –3.02 to 2.48; p=0.85).

These findings did not change even after statistical adjustment for antiparkinson medication use. Isradipine treatment did not show any effect on secondary outcomes. Adverse effects were also observed with isradipine, with oedema and dizziness being the most common.

The study was limited by the possible insufficient dosage for isradipine to “engage the target calcium channels associated with neuroprotective effects,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 08 Apr 2020

Guidelines for local pharmacists on what actions to take during the COVID-19 pandemic have been issued by the Malaysian Pharmaceutical Society (MPS).

Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Roshini Claire Anthony, 6 days ago

The use of a vaginal cleansing intervention prior to Caesarean delivery reduced the incidence of surgical site infections (SSIs), according to a study presented at ACOG 2020. However, the addition of intravenous (IV) azithromycin prophylaxis had no added impact on SSI rates.